A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

October 31, 2008

Conditions
Colitis, Ulcerative
Interventions
BIOLOGICAL

Single dose-group A

PF-00547659, single iv dose

BIOLOGICAL

Single dose-group A

PF-00547659, single iv dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Single dose-group A

PF-00547659, single iv dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Single dose-group A

PF-00547659, single dose

BIOLOGICAL

Single dose-group A

PF-00547659, single dose

BIOLOGICAL

Single dose-group A

PF-00547659, single dose

BIOLOGICAL

Single dose-group A

PF-00547659, single dose

BIOLOGICAL

Multiple dose-Group B

PF-00547659, multiple dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Multiple dose- Group B

PF-00547659, multiple dose

BIOLOGICAL

Multiple dose-Group B

PF-00547659, multiple dose

Trial Locations (18)

1200

Pfizer Investigational Site, Brussels

3000

Pfizer Investigational Site, Leuven

8000

Pfizer Investigational Site, Aarhus C

10117

Pfizer Investigational Site, Berlin

24105

Pfizer Investigational Site, Kiel

28040

Pfizer Investigational Site, Madrid

28222

Pfizer Investigational Site, Majadahonda

48129

Pfizer Investigational Site, Münster

93042

Pfizer Investigational Site, Regensburg

B-1070

Pfizer Investigational Site, Brussels

625 00

Pfizer Investigational Site, Brno

120 00

Pfizer Investigational Site, Prague

128 01

Pfizer Investigational Site, Prague

0027

Pfizer Investigational Site, Oslo

950 01

Pfizer Investigational Site, Nitra

08025

Pfizer Investigational Site, Barcelona

08035

Pfizer Investigational Site, Barcelona

08907

Pfizer Investigational Site, L'hospitalet DEL Llobregat

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00928681 - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter